ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0023

Hypophosphatasia May Be Misdiagnosed as Fibromyalgia: A Single Center Experience

Patil Injean1, Sandy Lee1 and Christina Downey1, 1Loma Linda University Medical Center, Redlands, CA

Meeting: ACR Convergence 2020

Keywords: fibromyalgia, Fracture

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Fibromyalgia & Other Clinical Pain Syndromes Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Hypophosphatasia (HPP) is a rare disease characterized by incomplete or defective bone mineralization due to a mutation in the alkaline phosphatase gene (ALPL).  Given the heterogeneity of gene mutation, phenotypes, and mode of inheritance, the disease has several presentations, including femoral and stress fractures, tooth loss, muscle weakness, chondrocalcinosis, nephrolithiasis, chronic pain, and osteoarthropathy, and chronic pain syndromes similar to fibromyalgia (FM). HPP diagnosis is marked by consistently low levels of alkaline phosphatase (ALP), elevated levels of inorganic phosphate, pyridoxal-5’- phosphate, a breakdown product of vitamin B6, phosphoethanolamine, and genetic testing. Although this patient population is prone to fractures and osteoporosis, the use of bisphosphonates is contraindicated due to worsening bone demineralization disease. There are very few case reports showing patients diagnosed with hypophosphatasia were initially misdiagnosed with fibromyalgia however there are no larger studies done on the subject. Our objective was to determine the prevalence of hypophosphatasia in a population of patients diagnosed with fibromyalgia

Methods: We performed a retrospective chart review of all patients 18 years or older at a single academic center diagnosed with FM based on ICD 10 Code “Fibromyalgia” M79.7 and at least one ALP level ≤ 35 were reviewed. Number of consecutively low ALP levels were noted. Gender, age, history of fragility fracture, bone mineral density screening, complete blood counts and medications were reviewed. For patients who have undergone HPP evaluation, genetic testing, and vitamin B6 levels were noted.   

Results: Out of 305 patients diagnosed with fibromyalgia and at least one low ALP level, 57 (19%) had at least 3 consecutively low measurements of ALP ≤ 35 while 12 (4%) of patients had at least 2 consecutively low measurements of ALP ≤25. Mean age was 52 (range 18-94), 41% of patients were female, and 59% were male. Of the patients with at least 3 consecutively low ALP ≤ 35, 23 (40%) had a history of fractures. Fifteen patients had bone density scans: 2 (4%) had normal results, 6(11%) had osteopenia, and 7 (12%) patients had osteoporosis.  No patients had Vitamin B6 levels checked. None of the patients had previous genetic testing for HPP. Of the patients with consistently low ALP levels, 16 (28%) were taking bisphosphonates. 

Conclusion: Up to 19% of FM patients in our population were found to have consistently low levels of ALP and high suspicion for undiagnosed underlying HPP. None of the patients had Vitamin B6 level checked or genetic testing done which suggests the diagnosis was not suspected despite the similarity of clinical symptoms and low ALP levels. It is increasingly important to diagnose these patients with HPP given treatment availability and to avoid bisphosphonate use to prevent worsening bone fragility. Furthermore, our data supports screening for this condition as a part of the initial workup of FM. 

Table 1: Characteristics of patients with Fibromyalgia and consistently low ALP


Disclosure: P. Injean, None; S. Lee, None; C. Downey, None.

To cite this abstract in AMA style:

Injean P, Lee S, Downey C. Hypophosphatasia May Be Misdiagnosed as Fibromyalgia: A Single Center Experience [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/hypophosphatasia-may-be-misdiagnosed-as-fibromyalgia-a-single-center-experience/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hypophosphatasia-may-be-misdiagnosed-as-fibromyalgia-a-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology